CasLoc logo
All Cases PTAB Litigations UPC Oppositions

In re: McKesson Corporation

1:24-mc-00460

Overview

Case Number 1:24-mc-00460
Filing Date 2024-09-26
Status Terminated
Termination Date 2024-10-15
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action Motion to Compel
Jury Demand None

Parties

Petitioner

Takeda Pharmaceuticals U.S.A., Inc. Operating Company

Represented By

5 Attorneys Listed

Porter F. Fleming

Email: pfleming@haugpartners.com

Jonathan A. Herstoff

Email: jherstoff@haugpartners.com

Edgar H. Haug

Email: ehaug@haugpartners.com

Camille Y. Turner

Email: cturner@haugpartners.com

Alan Richard Silverstein

Connolly Gallagher LLP

Tel: +1 (302) 757-7322

1201 N. Market St., 20th Floor

Respondent

McKesson Corporation NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

No Co-Pending Disputes Detected in Current Index

There are no other active filings for this patent family across our indexed PTAB, U.S. Court, UPC, or EPO databases.

Patents Involved

No asserted patent numbers detected in initial docket filings yet.

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

5

Dispositive

0

Granted

0

Denied

0

Pending / Review

5

Motions by Category

Procedural / Extension Motion 2 Motion to Compel Discovery 3

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
MOTION for Leave to File Exhibits 6-7 Under Seal - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Text of Proposed Order)(mpb) (Entered: 09/26/...
Entry #1 • 2024-09-26 Document →
Procedural / Extension Motion Pending / Under Review
DECLARATION of Alan R. Silverstein re 1 MOTION for Leave to file Exhibits 6-7 Under Seal - filed by Takeda Pharmaceuticals U.S.A., Inc. (mpb) Modified on 10/3/2...
Entry #2 • 2024-09-26 Document →
Motion to Compel Discovery Pending / Under Review
MOTION to Compel Third Party McKesson Corporation to Comply with Deposition Subpoena (filing fee $52, receipt number ADEDC-4508332) - filed by Takeda Pharmaceut...
Entry #3 • 2024-09-26 Document →
Motion to Compel Discovery Pending / Under Review
OPENING BRIEF in Support of 3 MOTION to Compel Third Party McKesson Corporation to Comply with Deposition Subpoena - filed by Takeda Pharmaceuticals U.S.A., Inc...
Entry #4 • 2024-09-26 Document →
Motion to Compel Discovery Pending / Under Review
[SEALED] Exhibits 6-7 to 3 MOTION to Compel Third Party McKesson Corporation to Comply with Deposition Subpoena - filed by Takeda Pharmaceuticals U.S.A., Inc. (...
Entry #8 • 2024-09-26 Document →

Docket Entries

(20 total)
Procedural / Extension Motion Pending / Under Review

MOTION for Leave to File Exhibits 6-7 Under Seal - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Text of Proposed Order)(mpb) (Entered: 09/26/2024)

Entry #1 • 2024-09-26
1
Procedural / Extension Motion Pending / Under Review

DECLARATION of Alan R. Silverstein re 1 MOTION for Leave to file Exhibits 6-7 Under Seal - filed by Takeda Pharmaceuticals U.S.A., Inc. (mpb) Modified on 10/3/2024 (nms). (Entered: 09/26/2024)

Entry #2 • 2024-09-26
1
Motion to Compel Discovery Pending / Under Review

MOTION to Compel Third Party McKesson Corporation to Comply with Deposition Subpoena (filing fee $52, receipt number ADEDC-4508332) - filed by Takeda Pharmaceuticals U.S.A., Inc. (Attachments: # 1 Exhibit 1-5, # 2 Text of Proposed Order, # 3 Civil Cover Sheet)(mpb) (Entered: 09/26/2024)

Entry #3 • 2024-09-26
1
Motion to Compel Discovery Pending / Under Review

OPENING BRIEF in Support of 3 MOTION to Compel Third Party McKesson Corporation to Comply with Deposition Subpoena - filed by Takeda Pharmaceuticals U.S.A., Inc. Answering Brief/Response due date per Local Rules is 10/10/2024. (mpb) Modified on 10/3/2024 (nms). (Entered: 09/26/2024)

Entry #4 • 2024-09-26
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Takeda Pharmaceutical Company Limited for Takeda Pharmaceuticals U.S.A., Inc. Other Affiliate Takeda Pharmaceuticals International AG for Takeda Pharmaceuticals U.S.A., Inc. filed by Takeda Pharmaceuticals U.S.A., Inc. (mpb) (Entered: 09/26/2024)

Entry #5 • 2024-09-26
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc